Selected scientific publications

KAND567, the first selective small molecule CX3CR1 antagonist in clinical development, mediates anti-inflammatory cardioprotective effects in rodent models of atherosclerosis and myocardial infarction. Presentation at ESC 2019 by Ioakim Spyridopoulus (Newcastle Upon Tyne, United Kingdom). Abstract and presentation is under embargo until September 3rd

T lymphocytes and fractalkine contribute to myocardial ischemia/reperfusion injury in patients. Boag SE, Das R, Shmeleva EV, Bagnall A, Egred M, Howard N, Bennaceur K, Zaman A, Keavney B, Spyridopoulos I. J Clin Invest. 2015 Aug 3;125(8):3063-76. doi: 10.1172/JCI80055. Epub 2015 Jul 13.

First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells. Hojjat-Farsangi M, Daneshmanesh AH, Khan AS, Shetye J, Mozaffari F, Kharaziha P, Rathje LS, Kokhaei P, Hansson L, Vågberg J, Byström S, Olsson E, Löfberg C, Norström C, Schultz J, Norin M, Olin T, Österborg A, Mellstedt H, Moshfegh A. Leukemia. 2018 Oct;32(10):2291-2295. doi: 10.1038/s41375-018-0113-1. Epub 2018 Mar 27.

Targeting PFKFB3 radiosensitizes cancer cells and suppresses homologous recombination. Gustafsson NMS, Färnegårdh K, Bonagas N, Ninou AH, Groth P, Wiita E, Jönsson M, Hallberg K, Lehto J, Pennisi R, Martinsson J, Norström C, Hollers J, Schultz J, Andersson M, Markova N, Marttila P, Kim B, Norin M, Olin T, Helleday T. Nat Commun. 2018 Sep 24;9(1):3872. doi: 10.1038/s41467-018-06287-x.

A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib. Daneshmanesh AH, Hojjat-Farsangi M, Ghaderi A, Moshfegh A, Hansson L, Schultz J, Vågberg J, Byström S, Olsson E, Olin T, Österborg A, Mellstedt H. PLoS One. 2018 Jun 1;13(6):e0198038. doi: 10.1371/journal.pone.0198038. eCollection 2018.